1-3 of 3
Zhongfa Liu, PhD
Close
Sort by
Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (ageā‰„60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD
Journal: Blood
Blood (2008) 112 (11): 2957.
https://doi.org/10.1182/blood.V112.11.2957.2957
Published: 2008
Journal Articles

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

Amy J. Johnson, PhD, Ryan Edwards, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Carlo M. Croce, MD, Natarajan Muthusamy, DVM, PhD, Ching-Shih Chen, PhD, Zhongfa Liu, PhD, Kenneth Chan, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2005) 106 (11): 51.
https://doi.org/10.1182/blood.V106.11.51.51
Published: 2005
Journal Articles

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

William Blum, MD, Rebecca Bruner-Klisovic, MD, Shujun Liu, PhD, John C. Byrd, MD, Zhongfa Liu, PhD, Kenneth K. Chan, PhD, Cheryl Kefauver, R.N., Lenguyen Huynh, Michael R. Grever, MD, Guido Marcucci, MD
Journal: Blood
Blood (2005) 106 (11): 1861.
https://doi.org/10.1182/blood.V106.11.1861.1861
Published: 2005